title: [Meningococcal disease: frequently asked questions].
abstract: On account of an increase of serogroup W135 meningococcal disease (M.D.) observed in Santiago, Chile, during last two years the medical community has experienced an avidity to update their knowledge about M.D. treatment and its prevention. In a queries and answers mode, the following topics on M.D. are presented: nasopharyngeal carriage and its importance, immunity and protection against the disease, reasons to choice ceftriaxone as the first line antibiotic in treatment, rationality and indications of chemoprophylaxis, fundamentals and advantages of conjugate vaccines, its indications, schedules, contraindications and decisions making in public health.
authors: Unidad de Infectología, Servicio de Pediatría, Hospital Luis Calvo Mackenna, Santiago, Chile. pepecofre@gmail.com
authors: José
authors: J
authors: Cofré
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D002677:Chile; D006801:Humans; D008589:Meningococcal Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D000900:Anti-Bacterial Agents; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate; D002443:Ceftriaxone